Skip to main content
Clinical Trials/NCT06500403
NCT06500403
Recruiting
Not Applicable

Noninvasive Tools for the Diagnosis of Porto-sinusoidal Vascular Disease: a Single-center, Prospective, Cohort Study

Nanfang Hospital, Southern Medical University1 site in 1 country1,000 target enrollmentFebruary 28, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Non-Cirrhotic Portal Hypertension
Sponsor
Nanfang Hospital, Southern Medical University
Enrollment
1000
Locations
1
Primary Endpoint
Searching for valid non-invasive tools for the diagnosis of PSVD
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Patients treated with platinum-based chemotherapy drugs have the probability of developing PSVD. The diagnosis of PSVD depends on liver biopsy. In addition, the level of portal vein pressure has guiding value in the diagnosis and prognosis of PSVD. Many studies have shown that liver and spleen stiffness have high accuracy in diagnosis and prognosis. The purpose of this study is to evaluate the efficacy of the combination of liver and spleen stiffness in the diagnosis of PSVD and to search for effective biomarkers for the diagnosis of PSVD through a single-center, prospective, observational study.

Detailed Description

PSVD is a supplement to non-cirrhotic portal hypertension and is defined as a class of diseases with characteristic pathological changes based on portal vein or hepatic sinuses abnormalities without cirrhosis. Some patients treated with platinum-based chemotherapy drugs will develop PSVD, which is clinically manifested as portal hypertension related complications. The diagnosis of PSVD depends on liver biopsy. In addition, the level of portal vein pressure has guiding value in the diagnosis and prognosis of PSVD. However, liver biopsy and pressure measurement are invasive methods. Many studies have shown that liver and spleen stiffness have high accuracy in diagnosis and prognosis. The purpose of this study is to evaluate the efficacy of the combination of liver and spleen stiffness in the diagnosis of PSVD and to search for effective biomarkers for the diagnosis of PSVD through a single-center, prospective, observational study.

Registry
clinicaltrials.gov
Start Date
February 28, 2024
End Date
December 31, 2029
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Received platinum chemotherapy for organ tumors;
  • Ages 18-80;
  • sign the informed consent voluntarily.

Exclusion Criteria

  • Liver pathology suggested cirrhosis;
  • Underwent liver transplantation;
  • Combined with hepatocellular carcinoma exceeding Milan criteria;
  • Complicated with severe heart, kidney, or lung failure;
  • Pregnant or lactating women;
  • Data is seriously missing;
  • Patients were judged not suitable for participation in this study by the researchers.

Outcomes

Primary Outcomes

Searching for valid non-invasive tools for the diagnosis of PSVD

Time Frame: 2 years

The sensitivity and specificity of the non-invasive models for the diagnosis of PSVD reached 85% and 60%, respectively

Secondary Outcomes

  • Patients died(3 years)
  • Patients underwent liver transplantation(3 years)
  • Patients developed portal-hypertension-related complications(3 years)
  • Patients reached the final follow-up time(3 years)

Study Sites (1)

Loading locations...

Similar Trials